Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 5/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214586 | 0.96 | USP2 (0.43) | USP2SMN1; SMN2MTORESR2MAPT | |
| SCHEMBL4209534 | 0.89 | ESR2 (0.45) | ESR2MAPTNR1H2GPR119 | |
| SCHEMBL8062860 | 0.88 | MAPT (0.42) | ESR2MAPTNR1H2GPR119 | |
| SCHEMBL4203005 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2MTORESR2MAPT | |
| SCHEMBL8057043 | 0.85 | MAPT (0.42) | ESR2MAPTNR1H2GPR119 | |
| SCHEMBL4204506 | 0.83 | NPSR1 (0.38) | SMN1; SMN2MAPTPIK3CAPIK3R1 | |
| SCHEMBL2110588 | 0.79 | MTOR (0.45) | USP2SMN1; SMN2MTORESR2MAPT | |
| SCHEMBL4209617 | 0.76 | MAPT (0.44) | ESR2MAPTNR1H2GPR119 | |
| SCHEMBL4195090 | 0.76 | USP2 (0.46) | USP2SMN1; SMN2MTORESR2MAPT | |
| SCHEMBL1832132 | 0.75 | MTOR (0.58) | USP2SMN1; SMN2MTORESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | USP2 2716/4885SMN1; SMN2 965/4885MTOR 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.